United Kingdom

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

6:00am GMT
Change (% chg)

¥-19 (-1.18%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for 4503.T


Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)


Beta: 0.59
Market Cap(Mil.): ¥3,468,732.00
Shares Outstanding(Mil.): 2,153.82
Dividend: 17.00
Yield (%): 2.05


  4503.T Industry Sector
P/E (TTM): 16.71 30.00 30.92
EPS (TTM): 96.36 -- --
ROI: 15.22 15.39 14.82
ROE: 16.14 16.57 16.24

BRIEF-Astellas terminates agreement with UMN Pharma for cell culture based influenza vaccine programs

* Says co terminates agreement with UMN Pharma Inc , for the co-development and Astellas' exclusive commercialization of ASP7374 and ASP7373, the cell culture based influenza vaccine programs in Japan

10 Jan 2017

BRIEF-Astellas to acquire Ganymed Pharmaceuticals 422 mln euros

* Atellas will pay eur 422 million to acquire 100% of equity in Gnymed

28 Oct 2016

BRIEF-Astellas to buy Ganymed Pharmaceuticals for 422 mln euros

* Astellas says to buy Ganymed Pharmaceuticals for EUR 422 million ($460 million)

28 Oct 2016

BRIEF-Astellas Pharma Inc's operating profit likely rose roughly 20% on the year for April-September half - Nikkei

* Astellas Pharma Inc's operating profit likely rose roughly 20% on the year to 160 billion yen ($1.54 billion) or so for April-September half - Nikkei

21 Oct 2016

Fitch Assigns First-Time 'BBB-' Rating to Beijing Capital Development

(The following statement was released by the rating agency) HONG KONG, October 20 (Fitch) Fitch Ratings has assigned Beijing Capital Development Holding (Group) Co., Ltd. (known by its abbreviated Chinese name Shokai Group) a Long-Term Foreign-Currency Issuer Default Rating (IDR) of 'BBB-' with Stable Outlook. Fitch has also assigned the homebuilder a foreign-currency senior unsecured rating of 'BBB-'. Fitch has also assigned Bright Galaxy International Limited's (Bright Galaxy) proposed US

20 Oct 2016

BRIEF-Astellas Pharma files lawsuit against patent infringement of Myrbetriq in U.S.

* Says the co and its subsidiaries jointly filed a lawsuit with the United States District Court against Actavis Elizabeth LLC and its affiliates, who filed an abbreviated new drug application for a generic version of Astellas' mirabegron (generic name) product sold under the trademark Myrbetriq in the U.S.

07 Oct 2016

BRIEF-Cytokinetics announces early termination of Hart-Scott-Rodino waiting period

* Announces Early Termination Of Hart-Scott-Rodino waiting period for expanded collaboration with astellas

29 Sep 2016

BRIEF-Astellas Pharma gets approval for medicine for hyperphosphatemia in Japan

* Says the co received a marketing approval of Kiklin Granules 86.2% for the indication of treatment of hyperphosphatemia in patients with chronic kidney disease in Japan

28 Sep 2016

Astellas, Vical herpes vaccine fails mid-stage study

Japan's Astellas Pharma Inc and San Diego-based Vical Inc said their experimental herpes vaccine failed a mid-stage study involving certain kidney transplant patients.

19 Sep 2016

BRIEF-Vical and Astellas study on CMV vaccine fails to meet its primary endpoint

* Results from study demonstrated that trial did not meet its primary endpoint

19 Sep 2016

Earnings vs. Estimates